CONNECT WITH US
HealthTech

HealthTech

After $1.9B impairment hit, Novartis stands by $12B bet on Avidity

Endpoints News logo

Published on

Add as a preferred source on Google
After $1.9B impairment hit, Novartis stands by $12B bet on Avidity

No­var­tis’ $12 bil­lion ac­qui­si­tion of Avid­i­ty Bio­sciences “re­mains ab­solute­ly on track,” CEO Vas Narasimhan said, af­ter the com­pa­ny dis­closed a $1.9 bil­lion …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

WuXi AppTec rais­es rev­enue fore­cast again in the face of DOD court case October 26, 2026

Corx­el to take oral GLP-1 pub­lic in the US via SPAC October 26, 2026

Ake­so de­tails ivonescimab's bil­iary can­cer suc­cess, draw­ing Keytru­da com­par­isons October 25, 2026

Be­yond the can­cer vac­cine, how did Mer­ck’s on­col­o­gy pipeline do at ES­MO?

EGFR-mu­tant lung can­cer is an ADC bat­tle­ground, with Chi­na lead­ing the charge

BioN­Tech, Du­al­i­ty­Bio pon­der next steps for HER2 ADC af­ter 'mod­est' breast can­cer re­sults



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.